HUGE — FSD Pharma Balance Sheet
0.000.00%
Last trade - 00:00- $18.52m
- $15.02m
- 16
- 28
- 40
- 18
Annual balance sheet for FSD Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 6.11 | 17.5 | 35.4 | 17 | 3.51 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1.59 | 0.161 | 0.501 | 0.374 | 7.42 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 8.76 | 26.9 | 45.9 | 17.9 | 11.1 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 9.19 | 0 | 0.168 | 0.261 | 0.12 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Total Assets | 44.2 | 42 | 63 | 38.4 | 17.5 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 6.99 | 5.58 | 8.7 | 7.83 | 4.57 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Liabilities | 7.1 | 5.66 | 8.83 | 7.87 | 4.24 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 37.1 | 36.3 | 54.1 | 30.5 | 13.2 |
| Total Liabilities & Shareholders' Equity | 44.2 | 42 | 63 | 38.4 | 17.5 |
| Total Common Shares Outstanding |